

FOR IMMEDIATE RELEASE

BAXTER HIGHLIGHTS NEW DATA AT KIDNEY WEEK INDICATING SHARESOURCE IS ASSOCIATED WITH A 77% LOWER RISK OF HOME DIALYSIS TECHNIQUE FAILURE

- *Additional key data presented at the congress indicates how **HDx** therapy enabled by **Theranova** dialyzer is helping advance “green” nephrology*
- *In total, Baxter supported 17 clinical presentations to advance scientific exchange at ASN: Kidney Week 2023*

DEERFIELD, Ill., November 6, 2023 – Baxter International Inc. (NYSE:BAX), a global innovator in kidney care and vital organ support, announced today new data indicating Baxter’s **Sharesource** remote patient management (RPM) digital platform, when used with an automated peritoneal dialysis (PD) system, is associated with a 77% reduction in risk of PD technique failure. Technique failure can be due to several factors and results in PD patients being switched to in-center dialysis. Additional key data show **HDx** therapy enabled by **Theranova** dialyzer provides expanded hemodialysis therapy, which can help reduce annual water consumption by 27% and annual electricity usage by 17%, and associated costs, in comparison with online HDF (hemodiafiltration).

The highlighted data was presented at ASN: Kidney Week, November 2-5, in Philadelphia, Pa., from abstracts—“*Role of Remote Monitoring in Automated Peritoneal Dialysis: Impact in SONG-PD (Standardized Outcomes in Nephrology-Peritoneal Dialysis) and Results from RPM-APD Multicenter Study*” [#SA-PO654] and “*Comparison of Utilities Consumption Between Different Modalities of In-Center Haemodialysis*” [#TH-PO291]—and were part of 17 scientific exchanges supported by Baxter during the conference.

“These new data help us further understand the essential role digital capabilities play in helping kidney patients stay on home dialysis longer, and the potential to support more sustainable care options,” said Professor Peter Rutherford, MB BS, PhD., head of global medical affairs, Kidney Care, Baxter. “Supporting continued research on proven technologies helps the collective efforts of industry, healthcare providers and policymakers better understand how to make meaningful advances toward increasing access to and improvements in the care we provide.”

About Sharesource Data

Baxter's **Sharesource** RPM platform is the first two-way, digital health solution that enables healthcare professionals to stay connected with their home dialysis patients. The new data presented at Kidney Week 2023 comes from a prospective observational multicenter cohort study that included 232 patients—176 were treated on APD with RPM, 56 were treated on APD without RPM—across 16 hospitals, over 12 months in Spain. In propensity matched patients, the use of **Sharesource** was associated with a 77% reduction in risk of technique failure (HR 0.23 95% CI 0.06-0.83, $p = 0.024$).

This evidence supplements earlier studies indicating **Sharesource** may reduce hospitalization rates by up to 39% and hospitalization days by up to 54%,¹ and is associated with a significant increase in time patients stay on therapy, by 3.2 months over the first two years.² The remote patient management platform—which currently supports more than 63,000 PD patients globally and has helped deliver more than 66 million treatments in 85 countries—allows healthcare providers to securely view their patients' recently completed home dialysis-related treatment data that is automatically collected after each PD session. Healthcare professionals can then act on this information by remotely adjusting their patients' home device settings without requiring them to make unplanned trips to the clinic.

About HDx Therapy Data

The **Theranova** dialyzer was designed to deliver **HDx** therapy, which filters a wider range of molecules from the blood than traditional hemodialysis (HD) filters by targeting efficient removal of large-middle molecules,^{3,4,5,6} allowing for filtration closer to that of the natural kidney.^{7,8} Many of these large-middle molecules have been linked to the development of inflammation, cardiovascular disease, and other comorbidities in dialysis patients.^{3,4,5,9}

The new in-center HD utility consumption study modeled the water consumption and electricity usage of high flux HD, **HDx** therapy enabled by **Theranova**, and online HDF within a dialysis unit in Saudi Arabia caring for 120 patients per year in 30 dialysis beds, running two shifts per day. Water consumption per year with online HDF was 4.1 million liters, but consumption was 27% lower with the use of **HDx** therapy. Furthermore, data indicate **HDx** therapy demonstrated 17% lower electricity and associated costs. This important environmental benefit of **HDx** therapy enabled by **Theranova** dialyzer adds to the clinical benefits and ease of delivery of this therapy.



The new data is added to an already robust compendium of clinical evidence that indicates HDx therapy enabled by **Theranova** may reduce the total cost of care, primarily driven by potential reduction of cardiovascular events, infections, medication usage, all-cause hospitalizations, hospitalization rate and length of stay.^{10,11,12,13,14,15}

About Baxter

Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on [X/Twitter](#), [LinkedIn](#) and [Facebook](#).

This release includes forward-looking statements concerning potential benefits associated with the Sharesource remote patient management platform. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: demand for and market acceptance for new and existing products; product development risks; inability to create additional production capacity in a timely manner or the occurrence of other manufacturing or supply difficulties (including as a result of natural disasters, public health crises and epidemics/pandemics, regulatory actions or otherwise); satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing, sterilization, or supply, or patient safety issues; changes in law and regulations; and other risks identified in Baxter's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

Baxter, Sharesource, HDx and Theranova are registered trademarks of Baxter International Inc.

###

Media Contact

Jill Carey-Hargrave, (224) 948-5353
media@baxter.com

Investor Contact

Clare Trachtman, (224) 948-3020

- ¹ Sanabria M, et al. Remote Patient Monitoring Program in Automated Peritoneal Dialysis: Impact on Hospitalizations. *Perit Dial Int.* 2019 Sep-Oct;39(5):472-478. doi: 10.3747/pdi.2018.00287. Epub 2019 Jul 23. PMID: 31337698.
- ² Sanabria et al., 2022. *Int'l Journal of Nephrology.* 2022; Article ID 8646775, doi:10.1155/2022/8646775.
- ³ Hutchison CA, et al. The Rationale for Expanded Hemodialysis Therapy (HDx). *Contrib Nephrol.* 2017; 191:142-52.
- ⁴ Neiryneck N, et al. An update on uremic toxins. *Int Urol Nephrol.* 2013; 45:139-50.
- ⁵ Duranton F, et al. European Uremic Toxin Work Group. Normal and pathologic concentrations of uremic toxins. *J Am Soc Nephrol.* 2012 Jul; 23(7):1258-70.
- ⁶ Rosner M, et al. Classification of Uremic Toxins and Their Role in Kidney Failure. *Clin J Am Soc Nephrol.* 2021;16(12):1918-1928
- ⁷ Zweigart C, et al. Medium cut-off membranes – closer to the natural kidney removal function. *Int J Artif Organs.* 2017; 40(7):328-334.
- ⁸ Boschetti-de-Fierro A, et al. MCO membranes: Enhanced Selectivity in High-Flux Class. *Scientific Reports* 2015; 5:18448.
- ⁹ Ronco C, et al. The rise of Expanded Hemodialysis. *Blood Purif.* 2017;44:1–VIII.. Doi: 10.1159/000476012.
- ¹⁰ Molano-Trivino A, Sanabria M, Vesga J, Buitrago G, Sanchez R, Rivera A. Effectiveness of medium cut-off vs high flux dialyzers: a propensity score matching cohort study. In *Nephrol Dial Transport.* 2021;36:486-U948.
- ¹¹ Cozzolino M, Magagnoli L, Ciceri P, Conte F, Galassi A. Effects of a medium cut-off (THERANOVA®) dialyser on haemodialysis patients: a prospective, cross-over study. *Clin. Kidney J.* 2021;14(1):382-389.
- ¹² Sanabria RM, Hutchison CA, Vesga, JI, Ariza JG, Sanchez R, Suarez AM. Expanded Hemodialysis and Its Effects on Hospitalizations and Medication Usage: A Cohort Study. *Nephron.* 2021;145(2):179-187.
- ¹³ Ariza JG, Walton SM, Suarez AM, Sanabria M, Vesga JI. An initial evaluation of expanded hemodialysis on hospitalizations, drug utilization, costs, and patient utility in Colombia. *Ther Apher Dial.* 2021;25(5):621-627.
- ¹⁴ Hadad-Arrascue F, Nilsson LG, Rivera AS, Bernardo AA, Cabezuelo Romero JB. Expanded hemodialysis as effective alternative to on-line hemodiafiltration: A randomized mid-term clinical trial. *Ther Apher Dial.* 2022;26(1):37-44.
- ¹⁵ Blackowicz MJ, Falzon L, Beck W, Tran H, Weiner DE. Economic evaluation of expanded hemodialysis with the THERANOVA 400 dialyzer: A post hoc evaluation of a randomized clinical trial in the United States. *Hemodialysis International.* 2022. <https://doi.org/10.1111/hdi.13015>